How does fingolimod (gilenya(R)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10191137" target="_blank" >RIV/00216208:11110/13:10191137 - isvavai.cz</a>

Alternative codes found

RIV/00179906:_____/13:10191137

Result on the web

<a href="http://dx.doi.org/10.3389/fneur.2013.00010" target="_blank" >http://dx.doi.org/10.3389/fneur.2013.00010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fneur.2013.00010" target="_blank" >10.3389/fneur.2013.00010</a>

Result language

angličtina

Original language name

How does fingolimod (gilenya(R)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Original language description

Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya(R)) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-na?ve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical ben

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Neurology

ISSN

1664-2295

e-ISSN

—

Volume of the periodical

4

Issue of the periodical within the volume

May

Country of publishing house

CH - SWITZERLAND

Number of pages

14

Pages from-to

1-14

UT code for WoS article

—

EID of the result in the Scopus database

—